Muaiad Kittaneh, Global Head of RandD and Scintific Strategy at Syneos Health, shared a post on LinkedIn:
“A few reflections from SGO2026 in San Juan.
The conversation in ovarian cancer is clearly evolving beyond individual data readouts toward strategy and execution.
ADCs continue to reshape the platinum-resistant setting, but the more important questions now are around sequencing, durability, toxicity, and resistance. As these agents move earlier, the field is already being pushed to think ahead to what comes next and how to sustain benefit over time.
Biomarker strategy is also shifting. HRD alone is no longer sufficient as a decision framework, and there is increasing focus on more actionable, target-driven biology, including FRα and other emerging markers that can better guide treatment decisions.
There is continued interest in MRD and ctDNA as tools to refine monitoring and inform therapy, but their role in routine practice, particularly in later-line settings, remains evolving rather than definitive.
The pipeline is deep, and the combination era is moving faster than our ability to test it efficiently. Trial design, patient selection, and operational simplicity will ultimately determine what succeeds.
What stood out just as much is hearing stories of resilience and lived experience which added a layer of clarity that no dataset can provide. It’s a reminder that behind every endpoint is a person navigating uncertainty, and that empathy is not separate from the science, it should shape how we advance it. Grateful to voices like Jess Wedel , and to physicians like Dr. Will Flanary who continue to humanize medicine and remind us, why this work matters.
The next phase in gynecologic oncology will not be defined only by better drugs, but by better strategy.”
Other Articles Featuring Muaiad Kittaneh on OncoDaily.